PDF(Pubmed)
Abstract：
The British Association for Psychopharmacology developed an evidence-based consensus guideline on the management of catatonia. A group of international experts from a wide range of disciplines was assembled. Evidence was gathered from existing systematic reviews and the primary literature. Recommendations were made on the basis of this evidence and were graded in terms of their strength. The guideline initially covers the diagnosis, aetiology, clinical features and descriptive epidemiology of catatonia. Clinical assessments, including history, physical examination and investigations are then considered. Treatment with benzodiazepines, electroconvulsive therapy and other pharmacological and neuromodulatory therapies is covered. Special regard is given to periodic catatonia, malignant catatonia, neuroleptic malignant syndrome and antipsychotic-induced catatonia. There is attention to the needs of particular groups, namely children and adolescents, older adults, women in the perinatal period, people with autism spectrum disorder and those with certain medical conditions. Clinical trials were uncommon, and the recommendations in this guideline are mainly informed by small observational studies, case series and case reports, which highlights the need for randomised controlled trials and prospective cohort studies in this area.
摘要：
英国精神药理学协会制定了一项基于证据的关于卡顿多症管理的共识指南。聚集了来自广泛学科的国际专家小组。证据来自现有的系统综述和主要文献。建议是根据这一证据提出的，并根据其强度进行了分级。该指南最初涵盖了诊断，病因学，卡顿的临床特征和描述性流行病学。临床评估,包括历史,然后考虑体检和调查。使用苯二氮卓类药物治疗，包括电惊厥治疗和其他药物和神经调节治疗。特别注意周期性紧张症，恶性紧张症,抗精神病药恶性综合征和抗精神病药引起的紧张症。关注特定群体的需求，即儿童和青少年，老年人,围产期的女性，患有自闭症谱系障碍的人和患有某些疾病的人。临床试验并不常见,本指南中的建议主要来自小型观察性研究，病例系列和病例报告，这凸显了该领域随机对照试验和前瞻性队列研究的必要性.
